Advertisement

Topics

Latest "IONTAS Limited" News Stories

22:31 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "IONTAS Limited" found in our extensive news archives from over 250 global news sources.

More Information about IONTAS Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about IONTAS Limited for you to read. Along with our medical data and news we also list IONTAS Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of IONTAS Limited Companies for you to search.

Showing "IONTAS Limited" News Articles 1–25 of 179

Monday 18th February 2019

Recce Successfully Raises AUD$1.8 million to Advance Lead Antibiotic Program

AUD$1.8m raised via placement from sophisticated and institutional investors Strengthened balance sheet to support Lead Antibiotic Program Strong support from existing and new shareholders Sydney, Australia – 18 February 2019 – Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), is pleased to announce that it has raised approximately AUD$1.8m (before costs) fro...


Friday 15th February 2019

Kiadis Pharma Notice of Extraordinary General Meeting of Shareholders

                                                                  Amsterdam, The Netherlands, 15 February 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that it has convened an extraor...

Herantis Pharma Plc is planning a directed share issue and prepares for a contemplated secondary listing on the First North Stockholm marketplace

Herantis Pharma Plc is planning a directed share issue to a limited number of investors and the company's directors and prepares for a contemplated secondary listing on the First North Stockholm marketplace Herantis Pharma Plc Company release 15 February 2019 at 9:00 am Not for publication or distribution, directly or indirectly, in or into Australia, South Africa, Hong Kong, Japa...


Thursday 14th February 2019

Quotient Limited to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

JERSEY, Channel Islands, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that today announced that the Company’s Chief Executive Officer, Franz Walt, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, 2019 at 10:00 a.m. EST at the Lotte New York Palace Hotel, in New York, NY. ...

Feedback Medical appoints radiologist and NHS England Clinical Entrepreneur Fellow as CEO

Cambridge, UK, 14 February 2019 - Feedback plc (AIM: FDBK, "Feedback", or the “Company”), the specialist medical imaging technology company, announces that its operating subsidiary, Feedback Medical Ltd, has appointed Dr Tom Oakley as its Chief Executive Officer. A qualified clinical radiologist, Dr Oakley has significant experience of successfully launching healthcare pr...

Tuesday 12th February 2019

SAW Diagnostics Receives £1.5M Innovate UK Funding to Support Commercialisation of its Point-of-Care Diagnostics Technology Platform

Glasgow, Scotland – 12 February 2019 – SAW Diagnostics Limited (SAW Dx), an emerging biological sample analysis and point-of-care diagnostic company, announced today that Innovate UK, the UK’s innovation Agency, has awarded the company a £1.5M grant in support of the company’s low-cost sample preparation system, for use in infectious disease detection and other appl...

Monday 11th February 2019

Kiadis Pharma to participate in a panel at Innovation for Health 2019

   Kiadis Pharma to participate in a panel at Innovation for Health 2019 Amsterdam, The Netherlands, February 11, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that it is scheduled to participate in a panel at the Innovation for Health 2019 Confer...

Wednesday 6th February 2019

Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP) First medicine approved in the U.S. specifically for the treatment of aTTP, a rare blood-clotting disorder Cablivi is the first U.S. approval for Sanofi's new rare blood disorders franchise PARIS - February 6, 2019 - The U...

Roche joins the World Federation of Hemophilia Humanitarian Aid Program

F. Hoffmann-La Roche Ltd / Roche joins the World Federation of Hemophilia Humanitarian Aid Program . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Hemlibra donation will provide prophylactic treatment to as many as 1,000 people with haemophilia A over five years in countries where there is little or no acces...

Monday 4th February 2019

Global Petroleum Hydrocarbon Resin Market Data Survey Report 2025 [Report Updated: 01011970] Prices from USD $1500

SummaryThe global Petroleum Hydrocarbon Resin market will reach Volume Million USD in 2018 with CAGR xx% 20182025. The main contents of the report including:Global market size and forecastRegional market size, production data and export importKey manufacturers manufacturing sites, capacity and production, product specifications etc.Major ApplicationMajor TypeKey manufacturers are included based o...

Kiadis Pharma appoints Dr. Robert Friesen as Chief Scientific Officer

                                                                   Kiadis Pharma appoints Dr. Robert Friesen as Chief Scientific Officer Amsterdam, The Netherlands, and Boston, Massachusetts, USA - February 4, 2019 - Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: ...

Thursday 31st January 2019

Genetic Technologies Limited Announces Research Collaboration with Two World-Renowned Medical Centres

MELBOURNE, Australia, Feb. 01, 2019 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company is pleased to announce the execution of a 3-way Research Agreement between its subsidiary Phenogen (100 % owned), Memorial Sloan Kettering Cancer Center (MSK), New York and the University of Cambridge, UK. This collaborative re...

Global Flexible Plastic Packaging Market Data Survey Report 2025 [Report Updated: 01011970] Prices from USD $1500

SummaryThe global Flexible Plastic Packaging market will reach Volume Million USD in 2018 with CAGR xx% 20182025. The main contents of the report including:Global market size and forecastRegional market size, production data and export importKey manufacturers manufacturing sites, capacity and production, product specifications etc.Major ApplicationMajor TypeKey manufacturers are included based on...

Wednesday 30th January 2019

Quotient Limited Provides an Update on Extended Immunohematology Microarray Performance and on the Commencement of the Initial Serological Disease Screening Field Trial together with Third Quarter Fiscal 2019 Results

Development data provides positive results for extended IH microarray panelField trial for initial Serological Disease microarray panel has commenced Reagent revenue growth of 15% in the quarter and 12% year to date JERSEY, Channel Islands, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT) (Quotient or the Company), a commercial-stage diagnostics company, today provided inter...

Tuesday 29th January 2019

STERIS to Announce Fiscal 2019 Third Quarter Financial Results on February 12, 2019

DERBY, U.K.  - January 29, 2019- STERIS plc (NYSE: STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2019 third quarter financial results at 10:00 a.m. Eastern Time on Tuesday, February 12, 2019.  The conference call can be heard live over the Internet at www.steris-ir.com or via phone by dialing 1-833-535...

Metrion Biosciences and LifeArc sign collaboration agreement for neuroscience-focused ion channel drug discovery

Novel small molecule programme aims to address major unmet medical need in neuroscience Collaboration focused on specific potassium ion channel target Cambridge and London, UK, 29 January 2019: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK medical research charity, today announced they have entered into a ...

Friday 25th January 2019

Bavarian Nordic Completes Enrollment of First Stage in Chordoma Phase 2 Trial

COPENHAGEN, Denmark, January 25, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today, that the first stage of a Phase 2 study of its novel, targeted cancer immunotherapy candidate, BN-Brachyury in the treatment of advanced chordoma has completed recruitment of the planned 10 patients ahead of schedule.  The multi-site trial, which holds the potential to serve as a regis...

Thursday 24th January 2019

Medtronic to Acquire EPIX Therapeutics, Expanding Its Cardiac Ablation Portfolio

DiamondTemp Ablation System Represents Disruptive RF Innovation DUBLIN - January 24, 2019 - Medtronic plc (NYSE: MDT) today announced that it has entered into a definitive agreement to acquire EPIX Therapeutics, Inc. (EPIX), a privately-held medical device company that designs and manufactures a novel, catheter-based, temperature-controlled cardiac ablation system for the treatment of...

BioPortfolio the life-science portal specializing in the biotechnology, pharmaceutical and healthcare sectors is seeking new ownership - an acquisition opportunity

24 January 2019 Dorchester, UK:  The founder of BioPortfolio Limited Peter Barfoot launched today a Private Memorandum outlining the opportunity to acquire the leading biotechnology, pharmaceutical and healthcare portal https://www.bioportfolio.com and associated research report store https://www.bioportfolio.co.uk. "The acquisition of the BioPortfolio websites will provide the purch...

Feedback plc - Half year results: Invoiced sales up 22%

Cambridge, UK, 24 January 2019 - Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces its unaudited half year results for the six months to 30 November 2018. Operational highlights (including post period-end) Feedback Medical sales momentum continues to grow with new TexRAD® sales into Czech Republic, B...

Tuesday 22nd January 2019

Acquisition Opportunity – BioPortfolio.com the leading “bio” life-science portal is seeking new ownership

22 January 2019 Dorchester, UK:  The founder of BioPortfolio Limited Peter Barfoot launched today a Private Memorandum outlining the opportunity to acquire the leading “bio” life-science portal https://www.bioportfolio.com and associated research report store https://www.bioportfolio.co.uk. The acquisition of the BioPortfolio websites will provide the purchaser with a vehic...

Friday 18th January 2019

Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders

Stevenage, UK – 18 January 2019 – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat serious disorders of the nervous system, today announced that the first milestone has successfully been achieved under Autifony’s option agreement with Boehringer Ingelheim. As announced previously, Boehringer Ingelheim acquired an exc...

Thursday 17th January 2019

Aleafia Health Completes Strategic Investment in Australia’s CannaPacific Pty Limited

Global Expansion Underway with 10% Equity Investment in Licensed Cannabis Cultivator CannaPacific among Australia’s only Federally Licensed Cultivators with projected 108,000 sq. ft. Greenhouse TORONTO, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSXV: ALEF: OTCQX: ALEAF, FRA: ARAH) (“Aleafia Health”) or the (“Company”) is announcing its global expansion with the closing o...

Medtronic Enrolls First Patient in Clinical Study to Assess Pain Control and Oral Opioid Elimination with Targeted Drug Delivery

Study Will Further Advance Understanding of Effectiveness and Tolerability of the SynchroMed(TM) II Intrathecal Drug Delivery System in Patients Who Have Weaned off Oral Opioids DUBLIN - January 17, 2019 - Medtronic plc (NYSE:MDT) today announced the first patient enrolled in the Embrace TDD (targeted drug delivery) clinical study that will evaluate the use of the SynchroMed(TM) II...

Wednesday 16th January 2019

Quotient Limited to Report Fiscal Third Quarter 2019 Financial Results and Host Conference Call

JERSEY, Channel Islands, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2018, will be released before market open on Thursday, January 31, 2019. Quotient will host a conference call to discuss its third quarter financial results at 8:30 a.m. East...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks